profit from every $100 of sales.
$0$100
iRhythm Technologies
$88.73-1.65% today
-49.2% in 1 year
1-year low $88.731-year high $189.25
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What iRhythm Technologies sold, what it kept, and what it did with the cash.
Sales went from $411 million in 2022 to $747 million in 2025, with -$44.6 million of profit last year.
SalesProfit
iRhythm Technologies vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| iRhythm Technologies | No profit yet | ||
 Boston Scientific | 22.0× · Fair price | ||
 Koninklijke Philips | 30.0× · Fair price | ||
 Steris | 31.9× · Expensive | ||
 Zimmer Biomet Holdings | 29.1× · Fair price |
AI analysis
An AI analyst reads iRhythm Technologies's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 411 | 493 | 592 | 747 | |
| 282 | 332 | 408 | 527 | |
| -87 | -114 | -115 | -53 | |
| -92 | -97 | -74 | -4 | |
| -116 | -123 | -113 | -45 | |
| -3.88 | -4.04 | -3.63 | -1.39 | |
| 68.5% | 67.3% | 68.9% | 70.6% | |
| -21.2% | -23.2% | -19.4% | -7.1% | |
| -28.3% | -25.0% | -19.1% | -6.0% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 448 | 433 | 931 | 1,020 |
| Cash | 79 | 36 | 420 | 236 |
| Total debt | 131 | 130 | 737 | 731 |
| Total liabilities | 208 | 223 | 841 | 867 |
| 240 | 210 | 91 | 153 | |
| 30 | 31 | 31 | 32 | |
| -23.8% | -27.7% | -9.5% | -2.7% | |
| -48.4% | -58.7% | -124.6% | -29.2% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -23 | -50 | 3 | 81 | |
| 30 | 40 | 49 | 46 | |
| -53 | -91 | -46 | 35 | |
| Dividends paid | – | – | – | – |
| 0 | 0 | 25 | 0 | |
| 58 | 77 | 76 | 88 |
Valuation
- –
- 19,966.2×
- –
- 23.0×
- 3.9×
- 85.3×
- –
- 1.2%
- -1.5%
- 0.0%
Profitability
- 70.6%
- -7.1%
- -6.0%
- 0.6%
- -2.4%
- -22.4%
- -20.6%
- -2.8%
- -2.5%
- 10.7%
Growth
- +22.1%
- –
- +213.0%
- –
- +2.2%
Financial health
- –
- 4.52
- 72.5%
- -1.6×
- 5.17
- 4.98
- 0.78
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 34%of 948
Bottom 17%of 871
Top 26%of 868
Top 50%of 985
What analysts expect
- Average price target
- $193.67
- Range
- $160.00 – $255.00
- 10 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 30, 2026 | -0.35 | -0.56 | +37.5% |
| Feb 19, 2026 | 0.17 | 0.02 | +750.0% |
| Oct 30, 2025 | -0.06 | -0.36 | +83.3% |
| Jul 31, 2025 | -0.32 | -0.53 | +39.6% |
| May 1, 2025 | -0.95 | -0.89 | −6.7% |
| Feb 20, 2025 | 0.01 | -0.29 | +103.4% |
| Oct 30, 2024 | -1.26 | -0.55 | −129.1% |
| Aug 1, 2024 | -0.61 | -0.92 | +33.7% |
News
Here’s Why Citi Downgraded iRhythm (IRTC) Despite 14.9% Revenue GrowthYahoo Finance · Nov 8, 2026iRhythm wins new Overweight at Piper on YTD pullbackSeeking Alpha · Oct 16, 2026iRhythm says June cyberattack accessed patient dataSeeking Alpha · Oct 2, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
22No pass
Benjamin Graham
20No pass
Philip Fisher
43No pass
Peter Lynch
38No pass
Joel Greenblatt
0No pass
Charlie Munger
23No pass
Terry Smith
32No pass
Questions about iRhythm Technologies
Is iRhythm Technologies a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the iRhythm Technologies AI analysis
What does iRhythm Technologies do?
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It is in Medical - Devices, based in San Francisco, CA, United States, with 2,400 employees.
Does iRhythm Technologies pay a dividend?
No. iRhythm Technologies does not pay a dividend at the moment.
Is iRhythm Technologies stock halal?
Yes. iRhythm Technologies passes our halal screen: its business is permitted and its debt is 25% of its market value, under the 30% limit. How we check
How has iRhythm Technologies stock done over the past year?
Down 49.2% over the past twelve months, to $88.73. It traded between $88.73 and $189.25 and is 53.1% below its high.
Who are iRhythm Technologies's competitors?
The largest listed companies in the same industry are Boston Scientific, Koninklijke Philips, Steris and Zimmer Biomet Holdings. The peers table on this page compares their profit, growth and price with iRhythm Technologies's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.